Crawford Investment Counsel Inc. Purchases 648 Shares of Mesa Laboratories, Inc. (MLAB)

Crawford Investment Counsel Inc. boosted its position in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 4.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 15,113 shares of the medical instruments supplier’s stock after buying an additional 648 shares during the quarter. Crawford Investment Counsel Inc. owned approximately 0.39% of Mesa Laboratories worth $2,805,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in MLAB. Massachusetts Financial Services Co. MA acquired a new stake in Mesa Laboratories in the 2nd quarter valued at approximately $12,064,000. Conestoga Capital Advisors LLC increased its position in shares of Mesa Laboratories by 10.9% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 475,439 shares of the medical instruments supplier’s stock worth $88,251,000 after purchasing an additional 46,717 shares during the last quarter. BlackRock Inc. increased its position in shares of Mesa Laboratories by 11.3% during the 2nd quarter. BlackRock Inc. now owns 210,585 shares of the medical instruments supplier’s stock worth $44,449,000 after purchasing an additional 21,299 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Mesa Laboratories during the 2nd quarter worth approximately $3,888,000. Finally, Royce & Associates LP increased its position in shares of Mesa Laboratories by 18.2% during the 2nd quarter. Royce & Associates LP now owns 102,430 shares of the medical instruments supplier’s stock worth $21,621,000 after purchasing an additional 15,778 shares during the last quarter. 68.47% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ:MLAB opened at $202.37 on Friday. The company has a market cap of $773.38 million, a price-to-earnings ratio of 32.75 and a beta of 0.27. Mesa Laboratories, Inc. has a twelve month low of $122.35 and a twelve month high of $224.95. The company has a current ratio of 1.72, a quick ratio of 1.29 and a debt-to-equity ratio of 0.29.

Mesa Laboratories (NASDAQ:MLAB) last posted its quarterly earnings results on Wednesday, October 31st. The medical instruments supplier reported $0.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.14. The firm had revenue of $24.87 million for the quarter, compared to analyst estimates of $25.00 million. Mesa Laboratories had a positive return on equity of 16.65% and a negative net margin of 1.60%. Research analysts forecast that Mesa Laboratories, Inc. will post 7.09 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, December 17th. Shareholders of record on Friday, November 30th will be given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, November 29th. Mesa Laboratories’s dividend payout ratio (DPR) is 10.36%.

Several research analysts have weighed in on the company. BidaskClub raised Mesa Laboratories from a “strong sell” rating to a “sell” rating in a research report on Wednesday, September 26th. TheStreet lowered Mesa Laboratories from a “b-” rating to a “c” rating in a research report on Tuesday, August 21st. Finally, ValuEngine lowered Mesa Laboratories from a “buy” rating to a “hold” rating in a research report on Thursday, October 4th.

In other Mesa Laboratories news, Director Seg Ventures, Llc bought 20,000 shares of the firm’s stock in a transaction that occurred on Sunday, December 30th. The shares were acquired at an average cost of $23.10 per share, with a total value of $462,000.00. Following the acquisition, the director now owns 120,000 shares of the company’s stock, valued at $2,772,000. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David M. Kelly sold 700 shares of the business’s stock in a transaction that occurred on Thursday, September 13th. The stock was sold at an average price of $190.01, for a total value of $133,007.00. Following the transaction, the director now directly owns 3,600 shares in the company, valued at $684,036. The disclosure for this sale can be found here. Insiders have acquired a total of 90,000 shares of company stock worth $2,097,600 in the last ninety days. Insiders own 15.00% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Crawford Investment Counsel Inc. Purchases 648 Shares of Mesa Laboratories, Inc. (MLAB)” was first reported by WKRB News and is owned by of WKRB News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/25/crawford-investment-counsel-inc-purchases-648-shares-of-mesa-laboratories-inc-mlab.html.

Mesa Laboratories Profile

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Featured Story: Dow Jones Industrial Average (DJIA)

Want to see what other hedge funds are holding MLAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mesa Laboratories, Inc. (NASDAQ:MLAB).

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply